Notice Number: NOT-CA-17-004

Key Dates
Release Date: November 17, 2016

Issued by
National Cancer Institute (NCI)

Purpose

This Notice is to inform the scientific community that the National Cancer Institute (NCI) is modifying RFA-CA-16-016, "Population-based Research to Optimize the Screening Process (PROSPR) (UM1)" to clarify the expectations regarding the minimal sizes of screening-eligible patient populations in participating healthcare systems.

The clarification explains that the stated minimum of 50,000 screening-eligible patients per health system should be met for PROSPR Research Centers focused on cervical and colorectal cancer. However, the respective numbers may be lower for Research Centers focused on lung cancer, as long as these numbers remain large enough to ensure sufficient statistical power to conduct the analyses proposed.

The following Section of RFA-CA-16-016 is revised accordingly.

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Under Heading: PROSPR II Objectives and Scope of the FOA
Sub-headings: General Requirements/Health Systems

Currently reads:
"In order to meet the goal of studying the cancer screening process in diverse populations, each PRC must include at least three distinct healthcare systems as data-contributing sites. Each system should be able to capture data for a minimum of 50,000 patients eligible for screening."

Modified to read:
"In order to meet the goal of studying the cancer screening process in diverse populations, each PRC must include at least three distinct healthcare systems as data-contributing sites. For the PRCs focused on cervical or colorectal cancers, each system should be able to capture data for a minimum of 50,000 patients eligible for screening. For the lung-focused PRC, data on a minimum of 50,000 age-eligible (i.e., 55-80 years) individuals per health system should be available, although it is expected that further assessment of smoking history and health status may result in fewer than 50,000 patients eligible for lung cancer screening. For all three cancer types, the anticipated number of screen-eligible individuals and the number screened must be large enough to ensure sufficient statistical power to conduct the analyses proposed by the PRC."

All other aspects of RFA-CA-16-016 remain unchanged.

Inquiries

Please direct all inquiries to:

V. Paul Doria-Rose, D.V.M., Ph.D. 
National Cancer Institute (NCI)
Telephone: 240-276-6904 
Email: doriarop@mail.nih.gov